Physician profile
Imran Hasanuddin
NPI 1942409370
$6,239.35
in general payments reported to CMS, 2019-2025
52 companies · $1,576 in 2025
The $1,576 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.48 · 2021: $526 · 2022: $1,086 · 2023: $1,546 · 2024: $1,492 · 2025: $1,576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,614.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,131.55 | 2021-2025 | |
| Amgen INC. | $680.59 | 2022-2025 | Evenity, Prolia, Repatha |
| Harmony Biosciences LLC | $518.13 | 2023-2025 | Wakix |
| Pfizer INC. | $504.74 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $484.61 | 2022-2025 | Xywav |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.93 | 2022-2024 | Jardiance, Stiolto Respimat, Cyltezo |
| Lilly USA, LLC | $203.51 | 2021-2025 | Jardiance, Zepbound, Taltz |
| Janssen Pharmaceuticals, INC | $203.04 | 2021-2022 | |
| Glaxosmithkline, LLC. | $183.79 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Axsome Therapeutics, INC. | $171.68 | 2023-2025 | Sunosi, Auvelity |
| Avadel Cns Pharmaceuticals, LLC | $159.86 | 2024-2025 | Lumryz |
| Novo Nordisk INC | $143.72 | 2021-2025 | Ozempic, Rybelsus |
| Paratek Pharmaceuticals, INC. | $100.39 | 2022-2023 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $96.32 | 2021 | |
| Astellas Pharma US INC | $82.28 | 2023-2025 | Veozah |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Hasanuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.